Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Canada.
Department of Medical Microbiology, Winnipeg, Canada.
J Infect Dis. 2019 Jun 5;220(1):41-45. doi: 10.1093/infdis/jiz068.
There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab')2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab')2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab')2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab')2 offers a potentially efficient therapeutic approach against EBOV disease in humans.
目前尚无针对致命埃博拉病毒（EBOV）的疫苗或经批准的治疗方法。我们研究了一种经过验证的技术平台，用于生产针对 EBOV 的多克隆 IgG 片段 F(ab')2。用含有 EBOV-Zaire/Makona 表面糖蛋白三聚体的纳米颗粒免疫的马产生了具有高中和活性的抗埃博拉 IgG 多克隆抗体。高度纯化的马抗埃博拉 F(ab')2 显示出对 2 种扎伊尔 EBOV 株（加蓬 2001 年和 Makona）的强烈交叉中和作用，并且体内 3 或 5 天每天进行 F(ab')2 腹腔内注射可使 BALB/c 小鼠对致死性 EBOV 攻击产生 100%的保护作用。快速制备纯化的马抗埃博拉 F(ab')2 为人类埃博拉病毒病提供了一种潜在有效的治疗方法。
